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Abstract
Inspired by the increasing burden of lung associated diseases in society and an growing demand to accommodate
patients, great efforts by the scientific community produce an increasing stream of data that are focused on
delineating the basic principles of lung development and growth, as well as understanding the biomechanical
properties to build artificial lung devices. In addition, the continuing efforts to better define the disease origin,
progression and pathology by basic scientists and clinicians contributes to insights in the basic principles of lung
biology. However, the use of different model systems, experimental approaches and readout systems may generate
somewhat conflicting or contradictory results. In an effort to summarize the latest developments in the lung
epithelial stem cell biology, we provide an overview of the current status of the field. We first describe the different
stem cells, or progenitor cells, residing in the homeostatic lung. Next, we focus on the plasticity of the different cell
types upon several injury-induced activation or repair models, and highlight the regenerative capacity of lung cells.
Lastly, we summarize the generation of lung mimics, such as air-liquid interface cultures, organoids and lung on a
chip, that are required to test emerging hypotheses. Moreover, the increasing collaboration between distinct
specializations will contribute to the eventual development of an artificial lung device capable of assisting reduced
lung function and capacity in human patients.
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Background
Although the lung has a low rate of cellular turnover dur-
ing homeostasis, it has a remarkable ability to regenerate
cells after injury [1]. Disruption of this regeneration
potential is the cause of several lung diseases. Therefore,
understanding the underlying mechanisms of the regen-
erative capacity of the lung offers potential in identifying
novel therapeutic targets. Much can be learned from stud-
ies on lung development as processes involved in the
differentiation of cell lineages during development are re-
capitulated during repair [2]. Recent advances in the iden-
tification of new cell markers, the analysis of cell fate by
in vivo lineage tracing experiments, the use of embryonic
and induced pluripotent stem cells, and improvements in
organoid cultures have increased the knowledge about the
presence of potential stem cells in the lung [3–6]. The
goal of this review is to survey the latest developments in
endogenous lung regeneration and bioengineering of lung
models for therapeutic applications in the future. We will
first provide an overview of the latest insights in lung pro-
genitor cells and their potential to differentiate into lung
epithelial cells, which is of interest for the in vivo regener-
ation of lung tissue. Next, we will discuss the plasticity of
the different epithelial cells in the lung and their potential
to contribute to epithelial regeneration. Finally, we will
highlight the possible clinical applications of this know-
ledge, focusing on different populations of stem cells, lung
mimics and tissue engineering.
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Potential epithelial stem cells of the lung
Different subsets of epithelial cells and potential stem
cell niches have been identified in the lung. The airways
of the human lung are lined by a pseudostratified epithe-
lium made up of basal cells, secretory cells (Scgb1a1+
club cells and goblet cells), ciliated cells and neuroendo-
crine cells (Fig. 1a). The trachea of the mouse, a
frequently used model in research, has a similar
architecture as the human airways. In human airways,
basal cells decrease in frequency from the large to the
distal airways [7]. The airways of the mouse and the re-
spiratory smallest bronchioles of the human lung are
covered by a cuboidal epithelium. This epithelium lacks
basal cells and contains ciliated cells, secretory cells and
neuroendocrine cells that are usually clustered in neuro-
endocrine bodies (NEBs) (Fig. 2a) [8]. The alveoli of
both human and mouse are composed of two functional
distinct cell types, flat and extended alveolar type I (AT-
I) cells to allow gas exchange and cuboidal alveolar type
II (AT-II) cells for surfactant protein production and
secretion (Fig. 2a) [2, 9]. New emerging technologies,
such as single cell RNA-sequencing and proteomic
analysis, revealed molecular signatures that hint at dif-
ferent subpopulations of type I and type II cells. It re-
mains to be seen whether such signatures reflect
functionally different cell types, or that it represents
similar cells at physiologically or metabolically different
phases. However interesting, this is not the focus of this
review, and therefore we only refer to the current litera-
ture [10–12].
Basal-like stem cells: the stem cells of the epithelium
Basal cells are being characterized by the expression of
Trp63, Ngfr, podoplanin (Pdpn, also known as T1α),
Fig. 1 Regeneration of pseudostratified airway epithelium of the lung. a The airways are lined by a pseudostratified epithelium consisting of
secretory cells (goblet and club cells), ciliated cells, neuroendocrine cells and basal cells. Goblet cells are abundant in the human epithelium, but
are rare in mice. b The relationship between the different epithelial cells during normal homeostasis. The basal cells are progenitor cells of the
pseudostratified epithelium which are heterogeneous for the expression of Krt14. The basal cell becomes a Krt8 positive luminal precursor cell
before further differentiation. A basal cell differentiate into secretory cells and neuroendocrine cells under homeostatic conditions.
Neuroendocrine cells are also capable to self-renew [162]. Scgb1a1+ secretory cells are a self-renewing population and can give rise to ciliated
cells. In homeostatic epithelium, there is a very low turnover of cells. It is likely that the dividing secretory cell population is sufficient to
regenerate ciliated cells in homeostatic condition. However, their generation from basal cells is not excluded. Upon allergen exposure, secretory
cells are the main source of goblet cells [163], but it is unknown whether basal cells can directly differentiate into goblet cells. (C). Upon depletion
of luminal cells by SO2exposure, basal cells proliferate and subdivide into two populations, N2ICD and c-myb positive, respectively, differentiating
into secretory and ciliated cells. After the loss of basal cells, secretory cells (de)differentiate into functional progenitor basal stem cells. In a normal
pseudostratified epithelium, only a few scattered goblet cells are present. Increases in goblet cells are observed upon immune stimuli and in
diseases like COPD. Lineage tracing studies show that goblet cells can arise from Scgb1a1+ secretory cells and recently a trans-differentiation of
foxj1+ ciliated cells to goblet cells was observed upon smoke exposure in culture
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GSIβ4 lectin and cytokeratin5 (Krt5). They have the
capacity to self-renew and to form secretory and ciliated
cells (Fig. 1b) [13–15]. Notch signaling plays a major role
in determining the differentiation of basal cells to either
the secretory lineage or the ciliated lineage [15–17]. A
small subset of the basal cells (<20 %) expresses Krt14
under homeostatic conditions. These cells are thought to
be a self-renewing population involved in maintenance of
the Krt5+ basal cell population. This proportion is highly
increased and becomes multipotent after naphthalene-
induced depletion of secretory cells [18, 19]. Lineage
tracing studies show that Krt14+ cells can directly regen-
erate secretory and ciliated cells [18, 20]. Recently, two
distinct populations of basal cells were identified in the
Fig. 2 Regeneration of distal and alveolar airway epithelium after injury. a The small airways lack basal cells and consist of cuboidal epithelium,
containing secretory and ciliated cells, as well as clusters of neuroendocrine cells. The cuboidal epithelium passes into a broncho-alveolar duct
junction which is the niche of broncho-alveolar stem cells. The alveolar epithelium consists of alveolar type I, type II cells and alveolar progenitor
cells. b Variant club cells (Cyp2f2−) are a variant of secretory cells that survive naphtalene injury and give rise to cyp2f2+ club cells. Lineage tracing
of Cgrp+ cells showed that after depletion of club cells by naphtalene injury neuroendocrine cells contribute to the regeneration of these cells.
At the broncho-alveolar duct junction, broncho-alveolar stem cells were isolated and shown to differentiate into bronchiolar and alveolar
lineages in culture (dashed lines). Scgb1a1+ cells have the potential to form alveolar type I and type II cells after bleomycin injury, but not after
hyperoxia-induced injury (dashed line). AT-II cells can self-renew and differentiate to AT-I cells. After pneumonectomy, a contribution of AT-I cells
to regenerate AT-II cells was observed. An alveolar progenitor cell expressing α6-β4 integrins can regenerate AT-II cells after injury. Yet another cell
type was identified expressing Sca1+ arising from AT-II cells and regenerating AT-I cells. Distal alveolar stem cells appear after severe injury and
give rise to secretory and alveolar cells
Schilders et al. Respiratory Research  (2016) 17:44 Page 3 of 16
adult lung using long-term lineage tracing experiments
and single-cell gene expression profiling: basal stem cells
(BSCs) and basal luminal precursor cells (BLPCs). Both
cell types are Krt5+ and Trp63+ with rare detection of
Krt14, indicating that Krt14 is not a robust marker for
stem cell identity [21]. However, the rapid up-regulation
of Krt14 post-injury suggests that Krt14 may be an im-
portant marker to identify activated stem cells in the re-
generating epithelium. Within homeostatic conditions,
BSCs divide via asymmetric division to produce one new
BSC and one BLPC, which can further differentiate into
a neuro-endocrine and secretory cell (Fig. 1b). The
BLPCs have a low or negligible rate of self-amplification,
lack any overt signs of differentiation, and are distinct
from BSCs by their expression of Krt8 [21]. This model
is consistent with a previous observation in human basal
cells addressing the potential of individual basal cells to
self-renew and differentiate [22]. Additionally, the emer-
gence of a Krt5+/Krt8+ parabasal cell population, which
have comparable characteristics as the previously de-
scribed BLPCs, was shown to be controlled by active
Notch3 signaling [16]. Notch3−/− mice showed an in-
crease in basal cells and parabasal cells, but not in multi-
ciliated and secretory cells, suggesting that Notch3 is
involved in restricting the expansion of the basal and
parabasal population [16]. Interestingly, binding of the
transcription factor Grainyhead-like 2 (Grhl2) to the pro-
motor region of Notch3 was observed, suggesting a role
for Grhl2 in the transcription of Notch3 [23]. BSC-
specific ablation of Grhl2 showed only a decrease in the
number of ciliated cells, but no other changes in the
morphology of the epithelium [24]. Whether Grhl2 is
important in the Notch3 dependent regulation of the
BSC and parabasal cell population still has to be ex-
plored. Krt8+/Krt5+ double positive cells were previously
identified in mice as a marker for progenitor cells upon
regeneration following injury induced by reactive oxygen
species and sulfur dioxide (SO2) [15, 25]. Interestingly,
using the SO2 injury model, it was observed that Trp63
+
basal cell populations segregate in subpopulations prior
to the formation of the Krt8+ progenitor cell. These div-
iding Trp63+ basal stem cell populations are either
N2ICD+ (the active Notch2 intracellular domain) cells
that differentiate into mature secretory cells, or c-myb+
cells that differentiate into ciliated cells (Fig. 1c) [26].
This specific segregation of progenitor cells was not
found in homeostatic epithelium, which indicates that
post-injury mechanisms may lead to different subsets of
progenitor cells compared to the homeostatic epithelium
[26]. A new study shows Trp73 as a regulator of ciliated
cell differentiation, which expression was observed in ter-
minally differentiated ciliated cells as well as in Trp63+
basal cells. This indicates a direct transition from basal
cell to ciliated cell as well as a segregation of epithelial
cell fate at the basal cell level [27]. The role for Trp73
in response to damage and the trigger that is responsible
for a Trp73+ basal cell to initiate ciliated cell differenti-
ation is not yet studied. This would be essential in un-
derstanding the role of Trp73 in the Trp63+ basal cell
population.
Clusters of Trp63+/Krt5+ cells, called distal alveo-
lar stem cells (DASCs), are present in the distal
airways after H1N1 influenza virus infection and
have the capacity to replace injured alveolar cells
(Fig. 2b) [28, 29]. Despite sharing similarity in
markers, the tracheal basal stem cells (TBSCs) and
DASCs show different fates in culture and in vivo
transplantation. The TBSCs give rise to more prox-
imal epithelium both in culture and in vivo, while
the DASCs can form alveolar spheres in vitro and
give rise to alveolar cells and secretory cells in vivo
[29]. Krt5 lineage tracing studies concluded that
these cells were not present before infection and
were generated as a response to injury [29]. In
addition to this finding, Vaughan and colleagues
proposed a lineage negative epithelial precursor
(LNEP) cell expressing Trp63+ and Krt5+ that helps
to regenerate the alveoli after bleomycin injury.
Transcriptional profiling of these cells indicate a very
heterogeneous population suggesting that different
cell types are present in the Trp63+/Krt5+ population
[30]. Moreover, active Notch signaling was required
to activate Trp63+/Krt5+ expression in LNEPs and
active Notch prevents the further differentiation into
AT-II cells [31]. This suggests that the hyperactive
Notch signaling observed in lung diseases possibly
contributes to failure of regeneration. In conclusion,
basal cells can function as tissue-specific stem cells
of the airway epithelium, but the heterogeneity in
the population of basal cells is not yet completely
understood. Since the identification of different sub-
sets of basal cells is studied using lineage-tracing
studies in mice, validation of these subsets of basal
cells in human lung is of importance. Differences in
progenitor populations are found in homeostatic epi-
thelium compared to damaged epithelium. This
suggests that in response to injury, molecular mech-
anisms are triggered that lead to the appearance of
different subsets of epithelial progenitor cells, per-
haps derived from one general homeostatic basal
cell. Currently, signaling pathways are being identi-
fied that influence the expansion of basal cells and
differentiation into specific cell types, but the precise
underlying molecular mechanisms still need to be
identified (Table 1). Furthermore, it is increasingly
recognized that basal cells not only contribute to
tissue repair, but are also a target for respiratory
pathogens and contribute to host defense against
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infection [32]. Further studies, including those aimed
at identifying subsets of basal cells that display these
properties, are needed to better understand the link
between this immune basal cell response and repair
of the epithelium.
Other epithelial progenitor cells
Basal cells are not the only identified multipotent cells
in the lung (Table 2). Variant club cells, a subset of
secretory cells that are positive for secretoglobin family
1a member 1 (Scgb1a1) and negative for Cyp2f2, have
been shown to self-renew and to differentiate into
Cyp2f2+ secretory cells after naphthalene injury [3, 33,
34]. Interestingly, another subset of Scgb1a1+ cells co-
expressing the AT-II marker surfactant protein C (Sftpc)
was shown to differentiate into bronchiolar and alveolar
lineages in vitro. These cells were called broncho-
alveolar stem cells (BASCs) and are located at the
broncho-alveolar duct junction (BADJ) (Fig. 2b) [35].
However, conflicting results are reported based on
lineage tracing of Scgb1a1+ cells after lung injury.
Scgb1a1+ cells differentiate into alveolar epithelial cells
after influenza and bleomycin-induced injury, but not
after hyperoxia-induced alveolar injury [34, 36]. This
contradiction could result from different subsets of cells
being labeled by the Scgb1a1-driven Cre driver, or from
the activation of different pathways by hyperoxia and
bleomycin. Cell-specific lineage tracing tools are re-
quired to give more clarity about the potential of BASCs
and the variant club cells.
Different alveolar progenitors and associating markers
have been identified in response to lung injury and are
summarized in Fig. 2b. AT-II cells expressing Sftpc are
capable of self-renewal and a small fraction of mature
type II cells can differentiate into AT-I cells in homeosta-
sis and after injury [37, 38]. Besides the progenitor po-
tential of AT-II cells, another progenitor subpopulation
for alveolar epithelial cells has been identified. These
cells co-express α6 and β4 integrins, but lack expression
of Scgb1a1 or Sftpc. They respond to lung injury and
can differentiate into AT-II cells and club cells. These
cells reside in the alveoli as well as in the BADJ and
their differentiation potential in vivo is most likely re-
stricted by their niches [39]. Furthermore, a distinct
population of Sca1+/Sftpc+ AT-II cells appeared at the
onset of repair after infection of the lung by Pseudo-
monas aeruginosa intratracheal instillation [40, 41]. Most
of these cells were negative for β4 integrin, Trp63 and
Scgb1a1, separating them from respectively other distal
progenitor cells and BASCs [28, 35, 39, 41]. Lineage tra-
cing experiments showed that Sca1+ AT-II cells may
arise from Sftpc+/Scgb1a1− cell and further differentiate
into AT-I cell (Fig. 2b). This conversion of Sca1+ AT-II
cells to AT-I cells depends on an active Wnt/β-catenin
pathway [42]. Taken together, several populations are be-
ing marked as progenitor cells and the activity of subsets
of progenitor populations seems to depend on their
niches and kind of epithelial damage. The current
Table 1 Overview basal-like stem cell populations
Cell type Subtypes Differentiation potential Signaling Cues
(Tracheal) Basal Stem Cells Trp63, Krt5, Krt14+/− Self-Renewal Notch [25], Hippo signaling [44]
Trp63, Krt5, Krt8 Basal Luminal Precursor Cell Notch 3 signaling [16], Grhl2 [24]
Neuroendocrine Notch1 [164, 165] and Hes1 [166]
Trp63, Krt5, N2ICD Club Notchhigh signaling [15], Notch1 [167], Notch2 [164]
Trp63, Krt5, c-Myb/Trp73 Ciliated Notchlow signaling [15], Notch 1 and 2 [164]
Distal Alveolar Stem Cells a Trp63, Krt5 Self-Renewal Increased Notch activity, Notch1 [31]
AT-II Inhibition of Notch [31]
Club
aOnly observed after H1N1 influenza virus infection or bleomycin induced injury, AT-II Alveolar Type II Cells
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challenge is to elucidate whether the different progenitor
cells are indeed different cells, or if these cells are vari-
ants of a single precursor cell that are induced by differ-
ent damaging agents. Single-cell RNA sequencing of the
developing distal lung epithelium has helped in defining
more precisely the different types of (progenitor) cells in
the distal region of the developing lung [12]. A similar
approach during regeneration of the proximal and distal
lung epithelium might provide additional clues on the
heterogeneity of epithelial cells upon repair.
Plasticity of the lung
Further complexity and challenges in lung regeneration
are generated by the plasticity of differentiated cells
(Table 3). Independent studies have pointed at the po-
tential of Scgb1a1+ secretory cells to dedifferentiate into
Trp63+/Krt5+ basal cells upon depletion of the basal cell
lineage or after damage of the lung epithelium [14, 43].
These dedifferentiated basal cells have the full capacity
to redifferentiate into ciliated or secretory cells (Fig. 1c).
The Hippo pathway and its down-stream effector Yap
are required for the dedifferentiation of secretory cells
[44]. Moreover, Yap has been shown to regulate stem
cell proliferation and differentiation during normal epi-
thelial homeostasis and regeneration upon injury in the
adult lung [44, 45]. Further research showed that the
nuclear-cytoplasmic distribution of Yap is important in
the differentiation of adult lung epithelium and during
development [16, 46]. Thus, Hippo signaling may be im-
portant in stimulating regeneration of the pseudostrati-
fied epithelium by controlling basal stem cell
differentiation as well as luminal cell plasticity.
Differentiation of Foxj1+ ciliated cells to mucus-
producing goblet cells was observed in human primary
bronchial epithelial cell culture after exposure to IL-13,
an important mediator in asthma [47]. Interestingly, this
plasticity was not confirmed by a Foxj1+ lineage tracing
study in mice using an ovalbumin-induced injury model
[48]. Either the difference of damage to the epithelium,
smoke versus ovalbumin, or the use of different species
could account for the different outcomes.
Previous lineage tracing studies using lysozyme M as
marker for mature AT-II cells already demonstrated that
AT-II cells can differentiate into AT-I cells [37]. More re-
cently, a plasticity AT-I cells after pneumonectomy has
been shown. To regenerate the alveoli, Hopx+ AT-I cells
proliferate and differentiate into Sftpc+ AT-II cells (Fig. 2b)
[49]. The formation of AT-II cells from Hopx+ AT-I cells in
organoid culture seems to be modulated by TGF-β signal-
ing [49]. These results suggest a bi-directional transition be-
tween the two types of mature alveolar cells. However, after
pneumonectomy the contribution of AT-I cells to regener-
ate AT-II cells is small (~10 %). Vice versa, approximately
16 % of regenerated AT-I cells are derived from Sftpc+ AT-
II cells, indicating that other cell sources also contribute to
re-alveolarization [49]. Thus, strategies for regeneration of
lung epithelium in disease, includes targeting of progenitor
cell populations and activating the plasticity or fate of dif-
ferentiated lung cells. Signaling cues to induce endogenous
lung regeneration are starting to be identified and might be
targets for disease therapies in the future. In line with initi-
ating differentiation through signaling, it has been demon-
strated that conversion of a specific cell type can be
induced by changing the expression of a single protein. Ec-
topic expression of Sox2 in AT-II cells changed its alveolar
cell type to a more proximal cell fate expressing Scgb1a1
and Trp63, even though the cells remained in the niche for
distal cells [50]. A similar approach was used to show the
plasticity of AT-I cells, where overexpression of Sox2 was
sufficient to reprogram AT-I cells towards a proximal air-
way cell fate with expression of Trp63 [51]. The differenti-
ation potential and plasticity of the lung epithelial cells as
described in the above sections are illustrated in Figs. 1 and
2 to show the complexity of the cells involved in regenerat-
ing the lung epithelium.
Regenerative medicine
Drugs to induce lung regeneration
Different signaling pathways are involved in either main-
taining a quiescent homeostatic or inducing a proliferat-
ing regenerating epithelium [3]. Signaling consists of
cross-talk and feedback loops between epithelial cells
but also between epithelial and mesenchymal cells. Such
interplay between mesenchymal and epithelial cells is for
example important in Hedgehog (Hh) signaling. In the
adult lung, Hh signaling balances between stimulating
proliferation and quiescence. In the homeostatic lung
Hh signaling is active to maintain quiescence, however
upon injury Hh signaling is inhibited to stimulate epithe-
lial proliferation [52]. A shift in the balance can lead to
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failure of repair but can also play a role in promoting
tumorigenesis [52, 53]. Several pathways involved in
lung development and regeneration are relevant in lung
disease, and drugs that either inhibit or induce these
pathways could have a beneficial effect for patients. Re-
cently, it was shown that deletion of Notch3 leads to an
expansion of basal cells, a hallmark of smokers and indi-
viduals with chronic obstructive pulmonary disease
(COPD) [16, 54, 55]. Interestingly, Notch3 down-
regulation was observed in smokers and in COPD lung,
making it a potential target for controlling the balance
between basal and luminal cells [16, 56] Candidate path-
ways for targeting in COPD include Hedgehog signaling,
Notch signaling, the retinoic acid pathway and the trans-
forming growth factor-β (TGF-β) pathway [57]. The
TGF-β pathway, as well as bone morphogenetic proteins
(BMPs), growth differentiation factors and activins are
also linked to asthma and these pathways could be po-
tential drug targeting candidates [58]. In COPD there is
mucus hypersecretion, and there are several ongoing
studies that examine the effect of already marketed
drugs on the production and secretion of mucus in
COPD models [59]. Recently, it was shown that interfer-
ence of Notch signaling with specific antibodies against
the ligands Jag1 and Jag2 results in an increase in cili-
ated cells at the expense of club cells [60]. Moreover,
jagged inhibition also reversed goblet cell hyperplasia,
which could potentially be important in COPD patients
to reduce the mucus production and to increase clear-
ance by the ciliated cells. Fibroblast growth factors
(FGFs) also play a role in regeneration of several tissues
including the lung [61]. FGF1 and FGF2 are thought to
play a role in the protection of epithelial stem cells and
lung maintenance, and are linked to pulmonary hyper-
tension. FGF1 is also thought to play a role in idiopathic
pulmonary fibrosis. FGF7 and FGF10 are involved in
lung regeneration and several different injury models
show that these FGFs are important for repair of the
lung. Several recombinant FGFs (FGF1, FGF2) and trun-
cated forms of FGFs (FGF7, FGF10) are already used in
clinical applications, like angiogenic therapies, coronary
heart disease and treatment of ulcers [61]. Although
these therapies are not yet available for lung diseases,
there may be some future perspectives, either in indu-
cing or inhibiting pathways involved in disease or by ac-
tivation of endogenous lung progenitor cells.
Stem cells
Stem cells are functionally characterized by their un-
differentiated state and their properties of self-renewal
and pluripotency to become specialized cells. Because
of these characteristics, they are appealing to be used
for the regeneration of damaged tissue. A distinction
can be made between embryonic stem cells (ESCs)
and adult stem cells. ESCs are derived from the inner
cell mass of the blastocyst and these cells have the
ability to differentiate into ectodermal, mesodermal
and endodermal cell types. Human ESCs could be
useful to study early embryonic development, for cell
replacement therapy, to study disease pathways, and
for drug discovery, although ethical and therapeutic
issues hamper the use of these cells. Besides ESCs,
several types of adult stem cells throughout the hu-
man body exist, like hematopoietic stem cells, intes-
tinal stem cells, mammary stem cells, olfactory stem
cells, mesenchymal stem cells, endothelial stem cells,
and neural stem cells. Adult stem cells are also cap-
able of self-renewal and may differentiate into several
cell types, but their differentiation potential is more
restricted [62–64]. As indicated, there is accumulating
evidence that differentiated cells show more plasticity
than previously thought. Moreover, the number of dif-
ferent progenitor cells in the lung is higher than pre-
viously expected, depending on the type of injury or
disease.
Induced pluripotent stem cells
In 2006, the group of Yamanaka introduced a method to
generate cells with properties similar to ESCs [65]. These
so-called induced pluripotent stem cells (iPSCs) are som-
atic cells that are reprogrammed into a multipotent stem
cell-like stage using only four different factors: Oct4, Sox2,
cMyc and Klf4 (Yamanaka factors) [64]. Culturing these
cells under distinct conditions induces several specialized
cell types. iPSCs can be used for numerous applications,
like disease modeling, regenerative medicine, drug discov-
ery, and toxicity studies [64, 66].
The lung is a very complex organ that consists of
many different specialized cell types, which makes it
challenging to generate human airway and alveolar epi-
thelial cells from iPSCs. First, definitive endoderm
should be derived from human iPSCs (hiPSCs), followed
by generation of anterior foregut endoderm [67]. From
this anterior endoderm, lung endoderm can be derived,
which can subsequently be guided towards bronchial
progenitor cells (Sox2+) or alveolar progenitor cells
(Sox9+), and finally towards bronchial or alveolar epithe-
lial faith [64]. Several studies have shown the differenti-
ation of ESCs and iPSCs into AT-II cells [68–73]. Other
groups have shown the differentiation of iPSCs into mul-
ticiliated cells [74], mature airway epithelium expressing
functional CFTR protein [75], multipotent lung and air-
way progenitors [76], purified lung and thyroid progeni-
tors [77], purified distal lung alveolar epithelium [78],
lung and airway epithelial cells [79], and lung and airway
progenitor cells [80]. An overview of these differenti-
ation protocols is given by Ghaedi and co-workers,
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although optimization is clearly required before these
cells may be used in clinical applications [64].
iPSCs may be used for the generation of patient-
specific disease models and (large scale) drug screen-
ing, as shown for example with cells derived from
patients suffering from cystic fibrosis [81]. A more
clinical use of iPSCs in lung disease therapy is not
yet approved and more knowledge is necessary before
this will be applicable [82].
Mesenchymal stem cells
Mesenchymal stem/stromal cells (MSCs) are adult
stem cells that have the potential to differentiate
into cells derived from the mesoderm lineage. MSCs
were first derived from bone marrow, but many
other sources are reported, including umbilical cord
blood, placenta, skin, liver and brain [83, 84]. MSCs
refer to a heterogeneous population of cells, making
it difficult to isolate them. Therefore, MSCs are de-
fined by a number of criteria based on the expres-
sion of specific cell surface antigens and their
functionality. Cells should express CD75, CD90 and
CD105, but not CD34, CD45, HLA-DR, CD11b,
CD19 and CD14. MSCs should be capable to differ-
entiate into chondrocytes, osteoblasts and adipocytes,
and should adhere to plastic for stable cell culture
[62, 83–85]. Recent studies have shown that MSCs
may differentiate in other cell types, including lung
cells, although this is still controversial [86, 87]. It
has been reported that MSCs can also be isolated
from the lung. Martin et al. reported the isolation of
MSCs from tracheal aspirates of neonates and from
adult broncho-alveolar lavage [88]. More recently,
Gong and co-workers isolated lung resident MSCs
and showed that these cells have the potential to dif-
ferentiate into AT-II cells [89]. MSCs derived from
other sources than the lung can also be differenti-
ated into alveolar epithelium. These alveolar cells
were generated from MSCs derived from human um-
bilical cord blood by culturing them in lung-specific
differentiation media [87].
There are many completed and ongoing clinical tri-
als using MSCs for applications in the nervous sys-
tem, heart, liver and kidney. In lung disease, therapies
with MSCs could be useful in bronchopulmonary dys-
plasia (BPD), COPD, acute respiratory distress syn-
drome and idiopathic pulmonary fibrosis [62, 83, 85,
90, 91]. However, given the low percentage of engraft-
ment of the instilled MSCs as demonstrated in animal
models, it is very likely that the beneficial effects of
MSC therapy are not due to the differentiation poten-
tial of MSCs itself, but rather due to paracrine and
immunomodulatory effects [83, 92–94].
Endothelial progenitor cells
There are two different subsets of endothelial progenitor
cells (EPCs), proangiogenic hematopoietic cells and
endothelial colony-forming cells (ECFCs) [95]. Proangio-
genic hematopoietic cells are derived from the bone
marrow and are involved in vascular repair. It is thought
that these cells circulate to injury sites and there facili-
tate formation of new vessels using paracrine mecha-
nisms, but lack direct vessel-forming ability. ECFCs are
rare circulating blood cells that have the potential to
generate cells that express genes from the endothelial
lineage. They also have the potential to form blood ves-
sels in vivo [95]. There is increasing evidence that EPCs
are involved in several lung diseases, including COPD,
BPD and pulmonary hypertension. Several lung injury
animal models have shown (partial) reversal of the in-
duced phenotype by systemic administration of EPCs,
including improvement of pulmonary function and re-
pair of the alveolar and vascular structure of the lung
[96–98]. These therapeutic effects could be caused by
structural conditions of the cells, by paracrine effects or
by a combination of both [82]. The interaction between
the pulmonary vasculature and the airways is important
for proper growth and regeneration of the lung
(reviewed in [99]). This was recently supported by the
identification of endothelial derived angiocrine signals
promoting alveolar regeneration after pneumonectomy
[100, 101]. The interactions between the vasculature and
epithelial cells upon repair are still elusive, but the iden-
tification of signaling molecules, like stromal cell-derived
factor-1 (SDF-1), may be important for potential therap-
ies. Systemic administration of EPCs has shown to be
beneficial in patients with primary pulmonary hyperten-
sion [102, 103]. Several pre-clinical and clinical trials are
ongoing to test the potential of using EPCs in lung dis-
ease therapies [82].
Besides the stem cells mentioned in this section, there
are also endogenous lung progenitor cells that were dis-
cussed in previous sections. All these different stem/pro-
genitor cells are potentially targets for therapeutic
strategies. While MSCs and EPCs could be effective be-
cause of their paracrine effects, iPSCs could be useful in
the development of lung mimics and tissue engineering.
Pathways involved in differentiation of lung progenitor
cells to other cell types and plasticity of these cells,
could be induced or inhibited by medication to induce
lung regeneration.
Lung mimics
Most studies on cell biology and tissue regulation
are based on 2D cell-culture models. Although these
models are valuable to answer specific scientific
questions, it is clear that these models have limita-
tions and fail to reconstitute the in vivo cellular
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microenvironment. Therefore, 3D cell-culture models
were developed, which mimic a more realistic tissue-
and organ-specific micro-architecture, although some
aspects, including tissue-tissue interfaces and a
mechanically active microenvironment are still miss-
ing. However, these models are very useful in
patient-specific disease models, drug-screening and
as a source of cells for transplantation [104].
Air-liquid interface cultures
Air-liquid interface (ALI) cultures mimic a more realistic
lung environment and make it possible for airway epithe-
lial cells to proliferate and differentiate in vitro. Whitcutt
et al. were the first to demonstrate mucociliary differenti-
ation using ALI cultures [105]. Culturing human airway
epithelial cells from patients, makes it possible to conduct
patient-specific research and drug-screening, for example
in cystic fibrosis and asthma [106, 107]. ALI cultures were
also used to model the effects of smoke exposure on
epithelial cells, which could be used to gain more insight
in mechanisms involved in the pathogenesis of COPD
[108, 109]. In 2015, a new computer-controlled ALI cul-
ture system was introduced in order to generate more
stable and comparable cultures, which may be useful for
large-scale toxicology studies [110].
Organoids
The concept of stem cell-derived organoids has
already been discovered in the 1950’s [111]. Organoid
models use the pluri- or multi-potent properties of
stem cells to differentiate into specialized cell types
and to self-organize into a 3D structure with organ-
or tissue-specific morphogenetic and histological
properties [112–114]. Overviews of tissues and dis-
eases modeled with organoids have been topics of
recent reviews [113–115]. These tissues include intes-
tinal buds, liver bud derivatives and retinal deriva-
tives. In the intestine, single Lgr5+ stem cells can be
isolated and grow into intestinal organoids [116].
Generation of lung organoids from one single stem
cell have not been reported yet, but several studies
have reported the generation of lung organoids
derived from human pluripotent stem cells (hPSCs),
primary respiratory cells and cell lines (reviewed in
[117]). These organoids include trachea/bronch
ospheres [15, 118–120], bronchiolar organoids [121],
bronchioalveolar organoids [120, 121], alveolospheres
[38, 120, 121], branching structures [122–124], alveo-
lar spheroids [125] and multi-lineage organoids [126].
In 2015, Dye et al. established a protocol to success-
fully generate lung organoids derived from hPSCs
(embryonic and induced). hPSCs were first differenti-
ated into anterior foregut spheroids, using ActivinA,
BMP and TGF-β inhibitors. This anterior foregut
endoderm was subsequently induced into a lung
lineage by modulating FGF and Hedgehog signaling.
In this way, the foregut spheroids gave rise to lung
organoids. These organoids possess both proximal
airway-like structures and immature alveolar airway-
like structures and are globally similar to fetal
human lung. These human lung organoids can be
used to study lung development and regeneration
[127]. Previously, tracheospheres were used to show
the capacity of basal cells to self-renew and the
potential to form secretory and ciliated cells [13].
Jain et al. used organoid cultures to show the poten-
tial of Hopx+ AT-I cells to form AT-II cells [49].
Furthermore, application of the Clustered Regularly
Interspaced Short Palindromic Repeats/Crispr associ-
ated protein (CRISPR/Cas) system in organoid cul-
ture might be a method to identify important players
in epithelial cell differentiation. Recently, this ap-
proach was used to identify the role of transcription
factor Grhl2 in the differentiation of ciliated cells
[24]. In the future, the loss or gain of function by
manipulation of genes in culture, will lead to more
insight in potential stem cell populations in the lung.
Organoids are very useful to answer specific ques-
tions about lung development and regeneration, but
so far they are not exposed to air, resulting in
incomplete differentiation of adult airway cells. Fur-
thermore, it does not allow to expose organoids to
air pollutants such as toxic gasses and micro- or
nanoparticles, making it impossible to use them to
study the effects of air pollutants on the airway
epithelium.
Lung-on-a-Chip
Organs-on-chips refer to bioengineered devices that
mimic tissue properties and functions in a well-
controlled environment [112]. Additionally, there are
also (acellular) lung-mimicking microfluidic devices
not specifically to study lung biology, but as respira-
tory assist devices or oxygenators [128]. Over the
past decade, several micro-engineered organ models
have been developed to study liver, kidney, intestine,
and heart, among others [129]. The first lung-on-a-
chip was introduced by Huh and co-workers, which
mimicked the vascular-alveolar structure by using
lung epithelial cells exposed to air on one side and
pulmonary vascular endothelial cells exposed to
flowing culture medium on the other side of a
permeable synthetic membrane (Fig. 3, [130]). This
model incorporated a microfluidics system and ap-
plied mechanical stress, and as such was capable of
mimicking gas exchange. However, it also has some
limitations, since it uses a flat 2D membrane, cell
lines instead of primary cells, and lacks interstitial
Schilders et al. Respiratory Research  (2016) 17:44 Page 9 of 16
fibroblasts and alveolar macrophages [130–132]. In
2015, Stucki and colleagues reported a lung-on-a-
chip with an integrated, bio-inspired respiration
mechanism. This model used primary human pul-
monary alveolar epithelial cells, which were co-
cultured with endothelial cells and exposed to a 3D
cyclic mechanical strain to mimic respiration [133].
The group of Blume developed a 3D model, consist-
ing of an air-liquid interface culture of human pri-
mary airway epithelial cells in a microfluidic culture
system. This system had a continuous exchange of
fluids and mediators, thereby simulating the intersti-
tial flow in the lung [134]. The power of using the
lung-on-a-chip approach includes the possibility of
connecting multiple devices, thereby creating a more
realistic lung mimic by integrating microfluidics,
stretch, curvature and primary cells. In addition to
air-liquid-interfaces and mimicking stretch during in-
and exhalation, the microfluidic approach allows to
apply pressure and shear flow profiles both in alveoli
and attached blood capillaries. Compartmentalized
microfluidic systems make bioartificial/-engineered
lung tissues also amenable for higher-throughput
screening of the influence/impact of concentrations
and mixtures of soluble factors in the blood/medium
compartment, and of gases and particles in the air
compartment
Tissue engineering
Although the above described systems are rapidly evolv-
ing, a huge hurdle is the generation of whole tissues and
organs. There are three important demands to success-
fully create tissues and organs: the source of cells, the
type of scaffold, and the composition of the extracellular
matrix (ECM). An appropriate mixture of cells should
be used for the recapitulation of cell-cell interactions
[135]. Appropriate scaffolds are necessary to obtain a 3D
structure and can be either synthetic or biological, and
biodegradable or non-biodegradable. In addition to the
template three-dimensional structure, there is mechan-
ical support and tissue instruction by engineered mech-
anical (e.g., through material or geometry-related matrix
elasticity or stiffness), geometrical/topographical (e.g.
through surface roughness or designed micro- or nano-
textures) or (bio)chemical cues (e.g. RGD-adhesion moi-
eties). An advantage of biodegradable scaffolds is that
these are absorbed by the body. However, in the case of
synthetic biodegradable scaffolds this may result in
acidic degradation products causing inflammation in the
surrounding tissue, e.g. when aliphatic polyesters like
poly(lactic acid) are used [136]. Compared to synthetic
scaffolds, biological scaffolds are more similar to the tis-
sue or organ that they should substitute, although bio-
logical scaffolds may lack sufficient mechanical
properties [137]. Different types of biological scaffolds
can be used like collagen, Matrigel® and decellularized
organs [137]. Decellularization of organs has to be done
in a proper way to as much as possible preserve all com-
ponents of the extracellular space/extracellular matrix
components and their instructive properties. Several
chemical, physical and enzymatical methods have been
described to achieve this [62]. After decellularization, a
process that does affect the extracellular matrix, the
scaffold can be recellularized. Cells from different
sources, as previously described, can be used for this
purpose: embryonic, fetal or adult stem cells, autologous
cells from the patient or iPSCs [62]. It is also possible to
use allogeneic cells, e.g. in the case of transplantation of
Fig. 3 Example of a human breathing lung-on-a-chip microdevice. Lung-on-a-chip microfluidic device with compartmentalized
microchannels to mimic a breathing lung (From Huh et al., “Reconstituting organ-level lung functions on a chip”, Science 2010;
328:1662–8. Reprinted with permission from the AAAS [100]). See original reference for detailed description of the figure. In brief, (a)
indicates the creation of mechanical breathing movements causing mechanical stretch of the membrane, (b) shows the physiology
of the normal breathing human lung, (c) and (d) show the assembly and etching of the microdevice, and (e) visualizes the actual
size of the device
Schilders et al. Respiratory Research  (2016) 17:44 Page 10 of 16
islets of Langerhans. There is also need for cells that are
involved in vascularization and innervation, and cells
with supportive, structural and barrier functions. Using
autologous cells would be ideal to prevent rejection of
the tissue-engineered organ in the patient, but could
cause difficulties in the case of genetic or metabolic dis-
orders [135]. Successful generation of tissue-engineered
autologous bladders [138] and bio-engineered skin sub-
stitutes [139] have been reported as well as successful
3D bioprinting of several tissues and organs including
multilayered skin, vascular grafts, heart tissue and tra-
cheal splints [135, 140].
The structure and composition of the ECM should re-
semble that of embryonic organogenesis. It has been
demonstrated that ECM signals are important to form
pulmonary tissue structures in vitro [141]. Other signals,
like cell-cell interactions, are also of importance to
mimic the micro-environment of the organ [112, 142].
Tracheal bioengineering
In patients with a tracheal defect of 50 % of total length
in adults or 30 % in children, artificial tracheal grafting
is required [143]. Several approaches for tracheal epithe-
lial differentiation have been tested, including co-
culturing of tracheal epithelial cells with fibroblasts or
adipose-derived stem cells [144–146] and cell sheet en-
gineering with tracheal epithelial cells [147, 148]. In spite
of the controversies and success rate, Macchiarini et al.
were the first group that transplanted a tissue-
engineered airway [149]. The group of Steinke produced
a bioartificial airway tissue using autologous primary
cells to re-endothelialize and reseed a biological vascu-
larized scaffold. After transplantation they observed
complete airway healing and no evidence of tissue dedif-
ferentiation [150]. Park and co-workers showed that hu-
man turbinated mesenchymal stromal cells cultured as
intact sheets were able to differentiate into tracheal epi-
thelium. These sheets were transplanted onto artificial
grafts and tested in a rabbit model. After 1 month, re-
generation of functional tracheal epithelium was ob-
served [143]. Still, considerable problems are observed
using tracheal grafts including failure to integrate and
the formation of cartilaginous tissue [4, 62].
Vascular bioengineering
Interactions between epithelium, mesenchyme and
endothelium are necessary for proper lung development
and regeneration. Blood vessels secrete angiocrine fac-
tors that are involved in these processes including
KLEIP, HIF-2α, VEGF, BMP-4, FGF, MMP14, EET and
TSP-1. Angiogenesis, the process where vessels are
formed from a pre-existing network, is important for
adult vascular homeostasis, regeneration and adaption.
Angiocrine signaling is necessary for this process [99].
The important role of the vasculature is also recognized
in tissue engineering. Ren et al. attempted to generate
transplantable rat lung grafts by seeding epithelial and
endothelial cells into the airway and vascular compart-
ments of a decellularized lung scaffold from the rat. The
major problem was poor vascular performance, causing
incomplete endothelial coverage of the scaffold vessels.
They optimized their protocol by co-seeding endothelial
and perivascular cells which resulted in an endothelial
coverage of 75 % [151]. Even during decellularization of
lung scaffolds, vascularization is important to preserve
the integrity of the scaffold [152]. Orlova and co-
workers showed that it is possible to generate endothe-
lial cells and pericytes from human PSCs. This could
provide a source of patient-specific vascular cells used in
vascular bioengineering [153].
Whole lung bioengineering
Bioengineering of the whole lung is more complex than
tracheal bioengineering due to the complexity of the
lung. Lungs that are not suitable for transplantation can
be decellularized and the scaffold can subsequently be
used for seeding cells to regenerate the lung. It is still
unknown which cell source is most suitable to repopu-
late the decellularized lung: MSCs, lung resident cells
or a combination of both. Recently, it was shown that
lung epithelial stem cells require co-culture with stro-
mal cells to proliferate and differentiate. Fibroblasts
have shown the highest efficiency in this support, and
also the tissue origin of these cells gives varying pat-
terns of support. Also, the use of FGFs and LIF-,
ALK5- and ROCK-inhibitors activates proliferation and
differentiation of quiescent lung stem cells [120]. Sev-
eral methods were developed to decellularize lungs of
rats, pigs, non-human primates and humans and to
subsequently recellularize these scaffolds [154–160]. An
overview of the currently available respiratory tract
models, including the used cell sources and scaffolds, is
reviewed by Nichols et al. [161].
Conclusions
Knowledge about potential stem cells in the lung has
markedly increased through various recent develop-
ments. One of the challenges will be to merge all the
data from different species and obtained with various
techniques into a simplified model of lung stem cells
and their role in the normal and diseased lung. Further-
more, a comprehensive view of all the (un)differentiated
cells is still missing, because our repertoire of cell spe-
cific markers is still inadequate to identify the various
cell types. One concern is that the use of different
markers in individual studies might lead to the miscon-
ception that several subpopulations of progenitor cells
exist, whereas there may possibly be only a few. In the
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future, the increase of cell-specific markers combined
with single-cell lineage tracing should improve the defin-
ition of different (stem) cell populations in the lung.
Additionally, a universal and unambiguous biological
read out system to test the quality and purity of lung
stem cells is also unavailable. So far, different systems,
such as ALI cultures, organoids and explants, are suc-
cessfully employed to fill this gap, but this makes it cum-
bersome to compare the various studies. Together with
ESCs, iPSCs, MSCs and EPCs, local lung stem or pro-
genitor cells could be used for diverse clinical applica-
tions in the field of regenerative medicine. Current
approaches to direct differentiation of stem cells, like
iPSCs and MSCs, do generate lung-specific cells, but the
specific lineages and the percentages of differentiated
cells vary substantially. Therefore, optimization, im-
provement and expansion of the existing protocols is
mandatory before clinical applications are possible. The
manipulation of stem cells, like iPSCs, is required and
useful for the development of lung mimics, for tissue en-
gineering and for the generation of complete lung tissue.
For tissue engineering applications, current scaffolds
need to be improved or alternative suitable scaffolds
need to be developed, which can be of synthetic and/or
biological origin, and should contain appropriate ECM
signals. Alternatively to bio-engineered lungs, specific
pathways involved in differentiation of lung progenitor
cells and plasticity of these cells may be targeted by
novel compounds to induce their contribution to lung
regeneration. Collectively, significant progress will be
made through the interaction between very distinct sci-
entific disciplines, such as developmental biology, bio-
medical engineering, and physics. These new and rapid
developments in lung repair and regeneration offers a
promising perspective for future patients with irrevers-
ible lung injury.
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